|Day Low - High||-|
|Year Low - High||-|
More Healthcare/Biotech NewsMarch 19, 2018
Johnson & Johnson Enters Binding Offer to Sell LifeScan, Inc. For Approx. $2.1 BillionMarch 14, 2018
Johnson & Johnson Vision Promotes the Patient Experience at FTC WorkshopMarch 8, 2018
HIIQ Heading To Roth Capital Growth Stock Conference in Dana Point, California March 13thFebruary 28, 2018
HIIQ Reports Record Q4 & Fiscal 2017 Financial & Operating ResultsFebruary 15, 2018
Health Insurance Innovations Surges Today & Schedules Earnings Call Feb. 28
Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years for breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.
Atossa is the only company in the WORLD attempting to conquer breast cancer the way they are and have stated “The best way to treat a disease is to prevent it in the first place.” They are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density. Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer. However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal with their topical endoxifen program is to treat high breast density with a local, topical drug.
Atossa is also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.
Their proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Their patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.
Have You read “Let’s Dance?” Vista Partners Weekly Market Update 3-24-18
Vista Partners has published “Let’s Dance?” Vista Partners Weekly Market Update 3-24-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe
Atossa Genetics Expands Breast Health Program With Mens’ Initiative
Gynecomastia is male breast enlargement and accompanying pain. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed resulting is higher estrogen levels that usually triggers
Happy St. Patty’s Day Weekend! “Lucky Charms For You?” Vista Partners Weekly Market Update 3-17-18 Now Available!
Vista Partners has published “Lucky Charms For You?” Vista Partners Weekly Market Update 3-17-18 and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s